A scalable approach to improving innovation efficiency

“One of the key outcomes is that you become a more efficient and strategic thinker. It helps you traverse many domains quickly, identify project kill criteria, and overcome hurdles. This leads to more rapid and higher impact outcomes.”Jacob Hooker, IDEA³ Faculty

Through the collaboration of innovation leaders in Madrid and Boston, M+Visión developed a unique innovation methodology called IDEA3. IDEA3 accelerates innovation and heightens its potential for impact. A core principle of IDEA3 is the integral involvement of diverse perspectives in the innovation process, from the clinician facing an unmet healthcare need to the entrepreneur who can bring a new technology to patient care.

IDEA3 helps medical technology innovators validate their projects by clearly identifying and defining medical needs. Often this includes a market pull—a key element that draws new technologies from ideas to implementation in patient care. Along the way, the IDEA3 method helps teams to de-risk their projects by strategically focusing on demostrated feasibility at each stage of development.

The IDEA3 Innovation Method helps teams—

  • Identify and precisely define medical needs
  • Compress development time and develop innovation
    ecosystems by engaging diverse lifecycle expertise
  • Make more strategic decisions about actions and resources
  • Drive change

IDEA3 Workshop

Bring IDEA3 to your organization

An IDEA3 Innovation Method workshop for innovation professionals, researchers, and executives, led by M+Visión faculty from Boston and Madrid, can help you implement the practice in your organization.

Learn more +

IDEA3 is the backbone of the mVision Catalyst and Converter programs, and it can be scaled to other programs an events, such as Hacking Medicine and workshops.

IDEA3 Faculty

An international team developed the IDEA3 method over years in the M+Visión Catalyst program.

Elfar Adalsteinsson, PhD
Massachusetts Institute of Technology

Jorge Bensadón Belicha, MBA
Vitro S.A.

David Boas, PhD
Massachusetts General Hospital,
Harvard Medical School

Peter Bryant, PhD
IE Business School

Deborah Burstein, PhD
Beth Israel Deaconess Medical Center, Harvard Medical School

Michael Dempsey
The Center for Integration of Medicine and Innovative Technology (CIMIT)

Isabela del Alcázar, PhD, MBM
BioCapital Advisors

Conor Evans, PhD
Massachusetts General Hospital,
Harvard Medical School

Javier Fernandez, MBA
BioCapital Advisors

Martha Gray, PhD
Massachusetts Institute of Technology

Peter Hansen, PhD
Union Biometrica Technology

Tim Harper
Cientifica

Juan Antonio Hernández Tamames, MSc, PhD
Universidad Rey Juan Carlos

Jacob Hooker, PhD
Massachusetts General Hospital,
Harvard Medical School

Petra Krauledat, PhD
PNP Research

María J. Ledesma Carbayo, PhD
Universidad Politécnica de Madrid

Norberto Malpica, PhD
Universidad Rey Juan Carlos

Julio Mayol, MD, PhD
Hospital Clinico San Carlos

Francisca Mulero, MD, PhD
Centro Nacional de Investigaciones Oncologicas (CNIO)

Timothy Padera, PhD
Massachusetts General Hospital,
Harvard Medical School

Juan José Ríos Blanco, MD, PhD
Hospital Universitario La Paz

Raul San Jose Estepar, PhD
Brigham and Women’s Hospital,
Harvard Medical School

Ángel Santos
CRB Inverbio

Bryan Strange, PhD
Alzheimer’s Disease Center of the Reina Sofia CIEN Foundation

Collin Stultz, MD, PhD
Massachusetts Institute of Technology

Zach Taylor, MBA
Third Rock Ventures

Jose Manuel Udias, PhD
Complutense University of Madrid (UCM)

Benjamin Vakoc, PhD
Massachusetts General Hospital,
Harvard Medical School

Juan José Vaquero, PhD
Universidad Carlos III de Madrid

Torunn Yock, MD
Massachusetts General Hospital,
Harvard Medical School